查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1676680

生物共軛市場：按生物共軛類型、按產品、按技術、按類型、按最終用戶、按應用、按治療領域 - 2025-2030 年全球預測

Bioconjugation Market by Bioconjugation Type, Offering, Technique, Type, End User, Applications, Therapeutic Areas - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年生物共軛市場價值將達81.3億美元，2024年將成長至90.6億美元，複合年成長率為12.19%，到2030年將達到182億美元。

主要市場統計數據
基準年 2023 年 81.3億美元
預計 2024 年 90.6億美元
預測年份 2030 182億美元
複合年成長率（%） 12.19％

生物共軛市場正處於變革時代的前沿，推動力來自創新技術的整合和各領域的應用擴展。本報告回顧了生物共軛技術的發展，並強調了該科學在藥物開發、診斷和研究中日益成長的重要性。近年來，突破為新方法鋪平了道路，使得更靈敏、更具選擇性和效率的結合方法成為可能，這些方法將成為下一代治療和診斷工具的支柱。

在如此動態的環境中，學術機構、生技公司、受託研究機構和製藥公司等相關人員受益於強大的生物共軛策略。隨著精度提高、性能增強和成本最佳化的趨勢明顯，該行業正在採用更全面的研發方法。這項新重點不僅將激發創新，還將培養多學科團隊之間的協作精神，為有可能重新定義現代醫學的開創性貢獻奠定基礎。

變革性轉變塑造生物共軛格局

近年來，生物共軛的環境發生了顯著變化。這些轉變的特點是數位化、對研發的大量投資以及先進分析方法的整合。從傳統的結合技術到更可靠、更有效的生物正交反應、點擊化學和酶促方法的演變證明了市場對科學進步的應對力。

技術創新很快就帶來了產品供應和最終用戶應用的策略調整。全球產業參與者擴大轉向專門的試劑、套件和服務模式來支援複雜的製造流程，包括 ADC 製程開發和原料藥製造。這些轉換不僅提高了共軛精度，而且還帶來了更高水準的可擴展性和可重複性。對穩健製程開發和分析驗證的日益重視，有助於公司滿足監管機構的多方面需求，並使其策略與治療和診斷應用的長期前景保持一致。

此外，點擊化學和基於酶的方法的改進凸顯了向減少副反應和提高產品穩定性的方法的轉變。這些進步使研究人員能夠探索新的標靶機制並最佳化有效載荷運送，最終加速從概念到市場的進程。簡而言之，產業相關人員必須不斷適應，在創新是成功主要驅動力的環境中保持競爭優勢。

塑造市場動態的詳細細分洞察

對市場區隔的考察揭示了生物共軛領域的複雜性和深度。市場根據生物共軛類型、產品、技術、產品類型、最終用戶、應用和治療領域進行細分。涵蓋的生物共軛類型包括寡核苷酸生物共軛（包括雙鏈和單鏈核苷酸）、胜肽生物共軛、聚合物生物共軛和蛋白質生物共軛。每種類型都針對特定的研究需求或臨床應用而量身定做，為各種實驗挑戰提供有針對性的解決方案。

細分市場的分析包括試劑和套件、ADC 製程開發、分析開發、原料藥製造、早期開發生物共軛服務、有效載荷和連接體製造、標靶劑或載體蛋白服務等廣泛的服務。提供如此廣泛的服務凸顯了對能夠客製化以滿足客戶獨特需求的多功能、專業化產品的需求。

基於技術的分割的討論擴展到醯胺鍵形成、生物正交反應、點擊化學、酶促方法和硫醇-馬來醯亞胺偶聯等方法。這些技術體現了創新化學和生物化學對提高產品性能同時確保安全性和可靠性的持續貢獻。

此外，我們區分了天然和合成的生物共軛物，並表明每個類別都符合特定的功能和監管要求。除此之外，還有基於最終用戶的細分市場，例如學術和研究機構、生物技術公司、受託研究機構和製藥公司，每個細分市場都有自己的優先事項和營運框架。

應用為市場區隔提供了另一個維度。生物共軛平台有多種用途，包括診斷、研究和開發以及治療應用。特別是治療應用，進一步分為抗生素、單株抗體和疫苗，展現出由解決複雜臨床挑戰的努力所推動的強勁圖景。

最後，基於治療領域的細分主要集中在心血管疾病、免疫學、感染疾病和腫瘤學，反映了生物共軛技術的廣泛影響。這些細分維度之間的相互作用有助於行業相關人員最佳化其投資組合，並開發高度針對性的產品以滿足不斷變化的市場需求。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 生物製劑和抗體藥物複合體(ADC) 的使用激增
    • 限制因素
      • 生物共軛研究的成本密集度和先進研究設備的初始投資
    • 機會
      • 生物共軛物合成進展
      • 增加公共和私營部門對生物共軛能力的投資
    • 任務
      • 對維持生物共軛物生產中的一致性和品管的擔憂
  • 市場區隔分析
    • 治療領域：生物共軛透過改善治療的傳遞和療效，在心血管疾病方面具有巨大優勢
    • 生物共軛類型：單鏈寡核苷酸因其在治療性介入中的多功能性而變得重要
    • 提供：鍵合製程的複雜設計和最佳化增強了 ADC 製程開發服務的可能性。
    • 技術：醯胺鍵形成技術由於其可靠性和所得結合物的強度而越來越被採用
    • 類型：合成生物共軛物由於其穩定性和可自訂性而變得越來越重要
    • 最終用戶：生物技術公司擴大採用生物共軛來提高其生物製藥產品的功效和特異性。
    • 應用：透過準確辨識癌細胞和腫瘤特異性抗原，生物共軛技術在癌症診斷中已廣泛應用
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會的
    • 技術的
    • 合法的
    • 環境

第6章 生物共軛市場依生物共軛型分類

  • 寡核苷酸生物共軛
    • 雙鏈核苷酸
    • 單鏈核苷酸
  • 肽生物共軛
  • 聚合物生物共軛
  • 蛋白質生物共軛

第7章 生物共軛市場依產品分類

  • 試劑和套件
  • 服務
    • ADC 製程開發
    • 分析與開發
    • 醫藥原料製造
    • 早期開發生物共軛服務
    • 有效載荷和鏈接器生產
    • 標靶藥物或載體蛋白服務

第 8 章。

  • 醯胺鍵形成
  • 生物正交反應
  • 點擊化學
  • 酵素法
  • 硫醇-馬來醯亞胺偶聯

第9章 生物共軛市場按類型

  • 天然生物複合物
  • 合成生物共軛物

第 10 章 生物共軛市場（依最終用戶分類）

  • 學術和研究機構
  • 生技公司
  • 合約研究組織
  • 製藥公司

第 11 章 生物共軛市場（依應用）

  • 診斷
  • 研究與開發
  • 治療
    • 抗生素
    • 單株抗體
    • 疫苗

第 12 章 生物共軛市場（依治療領域）

  • 心血管疾病
  • 免疫學
  • 感染疾病
  • 腫瘤學

第 13 章：美洲生物共軛市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

14. 亞太地區生物共軛市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第 15 章歐洲、中東和非洲生物共軛市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第16章 競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • AbbVie Inc.
  • Abcam plc by Danaher Corporation
  • Abzena Limited
  • Agilent Technologies, Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Bio-Techne Corporation
  • Biocon Limited
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Charles River Laboratories International, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Innovagen AB
  • Johnson & Johnson Services Inc
  • Lonza Group AG
  • Merck KGaA
  • Pfizer Inc.
  • Sanofi SA
  • Sartorius AG
  • Sorrento Therapeutics, Inc.
  • Sutro Biopharma, Inc.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd
Product Code: MRR-1B650A7892A1

The Bioconjugation Market was valued at USD 8.13 billion in 2023 and is projected to grow to USD 9.06 billion in 2024, with a CAGR of 12.19%, reaching USD 18.20 billion by 2030.

KEY MARKET STATISTICS
Base Year [2023] USD 8.13 billion
Estimated Year [2024] USD 9.06 billion
Forecast Year [2030] USD 18.20 billion
CAGR (%) 12.19%

The bioconjugation market is at the forefront of a transformative era, marked by a fusion of innovative technologies and expanding applications across various fields. This report outlines the evolution of bioconjugation techniques and highlights the increasing importance of this science in drug development, diagnostics, and research. Over the past few years, breakthrough advancements have paved the way for new methodologies, enabling more sensitive, selective, and efficient conjugation methods that serve as the backbone for next-generation therapeutics and diagnostic tools.

In this dynamic environment, stakeholders from academic institutions, biotechnology firms, contract research organizations, and pharmaceutical companies are reaping the benefits of robust bioconjugation strategies. With clear trends toward precision, enhanced performance, and cost optimization, the industry now embraces a more integrated approach to research and development. This renewed focus not only encourages innovation but also drives the collaborative spirit among multidisciplinary teams, setting the stage for groundbreaking contributions that hold the potential to redefine modern medicine.

Transformative Shifts Driving the Bioconjugation Landscape

Recent years have witnessed transformative shifts in the bioconjugation landscape. These shifts are predominantly characterized by digitization, focused investments in research and development, and the integration of advanced analytical methods. The evolution from traditional conjugation techniques to more reliable and efficient bio-orthogonal reactions, click chemistry, and enzymatic methods is a testament to the market's responsiveness to scientific advancements.

Technological innovation has been quickly followed by strategic realignment in product offerings and end-user applications. Global industry players are increasingly moving towards specialized reagents, kits, and service models that support complex manufacturing processes, including ADC process development and drug substance manufacturing. These transformative changes have not only improved the precision of conjugation but have also led to higher levels of scalability and reproducibility. The emphasis on robust process development and analytical validation means that companies can now address the multifaceted demands of regulatory bodies and align their strategies with the long-term outlook of therapeutic and diagnostic applications.

Furthermore, the ongoing improvements in click chemistry and enzyme-based techniques underscore the shift towards methodologies that offer reduced side reactions and enhanced product stability. This evolution is enabling researchers to explore novel targeting mechanisms and optimize payload delivery, ultimately accelerating the pathway from concept to market. In essence, industry participants must continuously adapt to maintain competitive advantage in a landscape where innovation is the primary driver of success.

Detailed Segmentation Insights Shaping Market Dynamics

A close examination of market segmentation reveals the complexity and depth of the bioconjugation sector. The market has been delineated based on bioconjugation type, offering, technique, product type, end user, applications, and therapeutic areas. In terms of bioconjugation type, the focus ranges from oligonucleotide bioconjugation, which encompasses both double-stranded and single-stranded oligonucleotides, to peptide bioconjugation, polymer bioconjugation, and protein bioconjugation. Each type is tailored to specific research needs and clinical applications, ensuring that targeted solutions are available for diverse experimental challenges.

When analyzing the offering, the market segments include reagents and kits, as well as a wide range of services such as ADC process development, analytical development, drug substance manufacturing, early development bioconjugate services, payload and linker manufacturing, and targeting agent or carrier protein services. This broad offering spectrum highlights the need for versatile and specialized products that can be customized to address unique client demands.

Technique-based segmentation extends the discussion to include methods such as amide bond formation, bio-orthogonal reactions, click chemistry, enzymatic methods, and thiol-maleimide coupling. These techniques illustrate the ongoing contribution of innovative chemistry and biochemistry in enhancing product performance while ensuring safety and reliability.

Furthermore, another layer of segmentation distinguishes natural bioconjugates from synthetic bioconjugates, with each category meeting specific functional and regulatory requirements. This is complemented by segments based on the end user, which include academic and research institutions, biotechnology companies, contract research organizations, and pharmaceutical companies, each with unique priorities and operational frameworks.

Applications provide yet another dimension to market segmentation. The bioconjugation platform supports a multitude of purposes including diagnostics, research and development, and therapeutic applications. Therapeutic applications, in particular, have been further divided into antibiotics, monoclonal antibodies, and vaccines, revealing a robust landscape fueled by effort to address complex clinical challenges.

Finally, segmentation based on therapeutic areas looks at cardiovascular disorders, immunology, infectious diseases, and oncology, reflecting the wide-ranging impact of bioconjugation technologies. The interplay between these segmented dimensions empowers industry stakeholders to optimize their portfolios and create highly targeted offerings that cater to evolving market demands.

Based on Bioconjugation Type, market is studied across Oligonucleotide Bioconjugation, Peptide Bioconjugation, Polymer Bioconjugation, and Protein Bioconjugation. The Oligonucleotide Bioconjugation is further studied across Double-Stranded Oligonucleotides and Single-Stranded Oligonucleotides.

Based on Offering, market is studied across Reagents & Kits and Services. The Services is further studied across ADC Process Development, Analytical development, Drug Substance Manufacturing, Early Development Bioconjugate Services, Payload & Linker Manufacturing, and Targeting Agent or Carrier Protein Services.

Based on Technique, market is studied across Amide Bond Formation, Bio-orthogonal Reactions, Click Chemistry, Enzymatic Methods, and Thiol-Maleimide Coupling.

Based on Type, market is studied across Natural Bioconjugates and Synthetic Bioconjugates.

Based on End User, market is studied across Academic & Research Institutions, Biotechnology Companies, Contract Research Organizations, and Pharmaceutical Companies.

Based on Applications, market is studied across Diagnostics, Research and Development, and Therapeutic. The Therapeutic is further studied across Antibiotics, Monoclonal Antibodies, and Vaccines.

Based on Therapeutic Areas, market is studied across Cardiovascular Disorders, Immunology, Infectious Diseases, and Oncology.

Key Regional Insights Unveiling Global Market Trends

The bioconjugation market exhibits significant regional variation, with key insights drawn from extensive research across major regions. In the Americas, the presence of advanced research infrastructures coupled with strong investments in biotech innovation fosters an environment conducive to pioneering therapeutic advancements and novel conjugation methodologies. The rigorous regulatory frameworks and favorable funding opportunities in this region provide a steady platform for industry growth and cutting-edge research.

Progress in Europe, the Middle East, and Africa is marked by robust academic-industry collaborations, a rich legacy in pharmaceutical sciences, and increasing support for innovation. European nations have consistently taken strides in driving regulatory excellence, which in turn has catalyzed the development of sophisticated bioconjugate products. In parallel, the Middle East and Africa are emerging as influential hubs, nurturing strategic partnerships and scaling up research initiatives that promise to impact the wider global market landscape.

The Asia-Pacific region represents a rapidly expanding market, characterized by increasing investments in biotech research, state-of-the-art manufacturing facilities, and a growing emphasis on regulatory harmonization. The region's emphasis on cost-effective manufacturing and scalability positions it as a critical player in global supply chains, especially as demand for high-quality bioconjugation products escalates. This diverse geographical spread highlights the significant role of regional trends in shaping global market dynamics, driving both competitive opportunities and collaborative ventures among industry leaders.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Pioneering Bioconjugation Market Developments

A multitude of established companies continue to influence the bioconjugation market significantly through extensive research, innovative product development, and strategic partnerships. Notable contributions have come from organizations such as AbbVie Inc. and Abcam plc by Danaher Corporation, whose research initiatives have spurred advancements in bioconjugation reagents and analytical precision. By focusing on breakthrough technologies in peptide and protein bioconjugation, these companies have also set new benchmarks for efficiency and reliability.

Other industry giants including Abzena Limited, Agilent Technologies, Inc., Amgen Inc., and AstraZeneca PLC have played pivotal roles in expanding the range of available techniques such as click chemistry and enzymatic methods. Their significant investments in ADC process development and early-stage bioconjugate services have not only accelerated product timelines but also improved the overall therapeutic efficacy.

Organizations like Bio-Techne Corporation, Biocon Limited, Boehringer Ingelheim GmbH, and Bristol-Myers Squibb Company are also actively engaged in refining methodologies and introducing innovative payload strategies. This is complemented by contributions from industry leaders like Charles River Laboratories International, Inc., Eli Lilly and Company, and F. Hoffmann-La Roche AG, whose collaborative industry insights have brought enhanced reliability in drug substance manufacturing and analytical development.

GlaxoSmithKline plc, Innovagen AB, Johnson & Johnson Services Inc., Lonza Group AG, and Merck KGaA further exemplify the diversified efforts in optimizing bioconjugation techniques for various modern therapeutic applications. The continuous evolution of the market is also reflecting in pioneering activities from Pfizer Inc., Sanofi S.A., Sartorius AG, Sorrento Therapeutics, Inc., Sutro Biopharma, Inc., Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd., whose endeavours in cutting-edge research have become central to redefining the standards of quality and performance in the field.

These key companies illustrate the strength of the competitive environment where deep technical expertise meets innovative product strategies, forming the backbone of industry progress and setting a path toward sustained market growth.

The report delves into recent significant developments in the Bioconjugation Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Abcam plc by Danaher Corporation, Abzena Limited, Agilent Technologies, Inc., Amgen Inc., AstraZeneca PLC, Bio-Techne Corporation, Biocon Limited, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Charles River Laboratories International, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Innovagen AB, Johnson & Johnson Services Inc, Lonza Group AG, Merck KGaA, Pfizer Inc., Sanofi S.A., Sartorius AG, Sorrento Therapeutics, Inc., Sutro Biopharma, Inc., Thermo Fisher Scientific Inc., and WuXi AppTec Co., Ltd. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to adopt a proactive approach that integrates robust R&D initiatives with agile business models. It is imperative to invest in advanced bioconjugation techniques and to continuously evaluate the efficiency of established processes such as click chemistry and enzymatic methodologies. Companies should consider forging strategic alliances that bridge academic insights with commercial innovation, thus ensuring a streamlined process from conception to regulatory approval.

Optimizing production capacities through scalable manufacturing platforms and fostering a culture of continuous improvement will help mitigate production risks. Leaders should prioritize portfolio diversification across various product types, including both synthetic and natural bioconjugates, and also tailor solutions to meet the distinct requirements of multiple end-user groups ranging from academic research centers to large pharmaceutical organizations.

Furthermore, a targeted approach focused on regional market trends can yield substantial strategic benefits. For instance, embracing innovations developed in regions with advanced technological infrastructures, while also seeking opportunities in emerging markets, can dynamically improve market reach and capitalize on latent demand.

In addition, it is recommended to refine process development capabilities in areas such as ADC process development, drug substance manufacturing, and analytical validation. This ensures regulatory compliance and enhances the overall commercial viability of bioconjugation products. Ultimately, leaders who balance innovative pursuits with strategic operational adjustments will be best positioned to capture rapidly growing market opportunities and foster long-term industry leadership.

Concluding Reflections on the Future of Bioconjugation

As the bioconjugation market continues to evolve, this report highlights key themes that will shape its future. The interplay of advanced conjugation techniques, diversified segmentation, and regional strategies underscores the market's robust potential for growth and innovation. Stakeholders across the board-from academic and research institutions to pharmaceutical and biotechnology companies-are embracing technological advancements and strategic partnerships to drive market momentum.

Key observations reveal that the shift towards more efficient, reliable, and scalable conjugation methods is no longer optional but essential to remain competitive. Enhanced product offerings, meticulous segmentation analysis, and a clear understanding of global regional dynamics are crucial for navigating the complex bioconjugate ecosystem. The continuous evolution in both product and service dimensions is not only indicative of current market demands but also a harbinger of future advancements.

This concluding analysis reinforces the idea that innovation is at the heart of market progress. By integrating best practices from diverse sectors and focusing on continuous improvement, industry players can drive sustainable growth. The strategic alignment of R&D initiatives with commercial objectives will serve as a catalyst for future success, ensuring that the bioconjugation market remains at the cutting edge of scientific and technological innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Surge in the use of biotherapeutics & antibody-drug conjugates (ADC)
    • 5.1.2. Restraints
      • 5.1.2.1. Cost-intensive nature of bioconjugation research and the initial investment for advanced research equipment
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements for synthesizing the bioconjugates
      • 5.1.3.2. Growing investment from public & private sector in bioconjugation capabilities
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with maintaining consistency and quality control in bioconjugate manufacturing
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapeutic Areas: Significant benefits of bioconjugation in cardiovascular owing to improved delivery and efficacy of therapeutic
    • 5.2.2. Bioconjugation Type: Growing significance of single-stranded oligonucleotides due to enhanced versatility in therapeutic interventions
    • 5.2.3. Offering: Rising potential of ADC process development services owing to intricate design and optimization of conjugation processes
    • 5.2.4. Technique: Increased adoption of amide bond formation technique due to reliability and the strength of the resulting conjugates
    • 5.2.5. Type: Growing significance of synthetic bioconjugates due to their stability and customization capabilities
    • 5.2.6. End User: Emerging incorporation of bioconjugation in biotechnology companies to enhance the efficacy and specificity of their biopharmaceutical products
    • 5.2.7. Applications: Proliferation of bioconjugation in cancer diagnostics owing to precise identification of cancerous cells and tumor-specific antigens
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Bioconjugation Market, by Bioconjugation Type

  • 6.1. Introduction
  • 6.2. Oligonucleotide Bioconjugation
    • 6.2.1. Double-Stranded Oligonucleotides
    • 6.2.2. Single-Stranded Oligonucleotides
  • 6.3. Peptide Bioconjugation
  • 6.4. Polymer Bioconjugation
  • 6.5. Protein Bioconjugation

7. Bioconjugation Market, by Offering

  • 7.1. Introduction
  • 7.2. Reagents & Kits
  • 7.3. Services
    • 7.3.1. ADC Process Development
    • 7.3.2. Analytical development
    • 7.3.3. Drug Substance Manufacturing
    • 7.3.4. Early Development Bioconjugate Services
    • 7.3.5. Payload & Linker Manufacturing
    • 7.3.6. Targeting Agent or Carrier Protein Services

8. Bioconjugation Market, by Technique

  • 8.1. Introduction
  • 8.2. Amide Bond Formation
  • 8.3. Bio-orthogonal Reactions
  • 8.4. Click Chemistry
  • 8.5. Enzymatic Methods
  • 8.6. Thiol-Maleimide Coupling

9. Bioconjugation Market, by Type

  • 9.1. Introduction
  • 9.2. Natural Bioconjugates
  • 9.3. Synthetic Bioconjugates

10. Bioconjugation Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Research Institutions
  • 10.3. Biotechnology Companies
  • 10.4. Contract Research Organizations
  • 10.5. Pharmaceutical Companies

11. Bioconjugation Market, by Applications

  • 11.1. Introduction
  • 11.2. Diagnostics
  • 11.3. Research and Development
  • 11.4. Therapeutic
    • 11.4.1. Antibiotics
    • 11.4.2. Monoclonal Antibodies
    • 11.4.3. Vaccines

12. Bioconjugation Market, by Therapeutic Areas

  • 12.1. Introduction
  • 12.2. Cardiovascular Disorders
  • 12.3. Immunology
  • 12.4. Infectious Diseases
  • 12.5. Oncology

13. Americas Bioconjugation Market

  • 13.1. Introduction
  • 13.2. Argentina
  • 13.3. Brazil
  • 13.4. Canada
  • 13.5. Mexico
  • 13.6. United States

14. Asia-Pacific Bioconjugation Market

  • 14.1. Introduction
  • 14.2. Australia
  • 14.3. China
  • 14.4. India
  • 14.5. Indonesia
  • 14.6. Japan
  • 14.7. Malaysia
  • 14.8. Philippines
  • 14.9. Singapore
  • 14.10. South Korea
  • 14.11. Taiwan
  • 14.12. Thailand
  • 14.13. Vietnam

15. Europe, Middle East & Africa Bioconjugation Market

  • 15.1. Introduction
  • 15.2. Denmark
  • 15.3. Egypt
  • 15.4. Finland
  • 15.5. France
  • 15.6. Germany
  • 15.7. Israel
  • 15.8. Italy
  • 15.9. Netherlands
  • 15.10. Nigeria
  • 15.11. Norway
  • 15.12. Poland
  • 15.13. Qatar
  • 15.14. Russia
  • 15.15. Saudi Arabia
  • 15.16. South Africa
  • 15.17. Spain
  • 15.18. Sweden
  • 15.19. Switzerland
  • 15.20. Turkey
  • 15.21. United Arab Emirates
  • 15.22. United Kingdom

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2023
  • 16.2. FPNV Positioning Matrix, 2023
  • 16.3. Competitive Scenario Analysis
    • 16.3.1. Lonza expands U.S. biologics capacity with USD 1.2 Billion acquisition of Roche's vacaville site
    • 16.3.2. Abzena expands partnership with proteoNic to standardize 2G UNic technology
    • 16.3.3. Abzena invests USD 5 million to enhance bioconjugation and ADC capacities at bristol facility
    • 16.3.4. WuXi XDC Commences construction of Singapore facility to boost bioconjugate development
    • 16.3.5. AstraZeneca's strategic acquisition of Fusion Pharmaceuticals to enhance Radioconjugate cancer therapies
    • 16.3.6. Samsung Biologics and LegoChem Biosciences collaborate on antibody-drug conjugate development
    • 16.3.7. Novo holdings strategic acquisition of Catalent to enhance bioconjugation capabilities
    • 16.3.8. OnCusp Therapeutics garners USD 100M Series A funding for advancing CUSP06 ADC and expanding oncology innovations
    • 16.3.9. Piramal Pharma Solutions boosts global bioconjugation capabilities with Pound 45 million ADC expansion
    • 16.3.10. GeneQuantum and BioMap partner to revolutionize ADC therapeutics with AI-driven bioconjugation
    • 16.3.11. Nona Biosciences and GeneQuantum partner to advance next-gen bioconjugate drug discovery
  • 16.4. Strategy Analysis & Recommendation
    • 16.4.1. WuXi AppTec Co., Ltd
    • 16.4.2. Lonza Group AG
    • 16.4.3. Merck KGaA
    • 16.4.4. Thermo Fisher Scientific Inc.

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Abcam plc by Danaher Corporation
  • 3. Abzena Limited
  • 4. Agilent Technologies, Inc.
  • 5. Amgen Inc.
  • 6. AstraZeneca PLC
  • 7. Bio-Techne Corporation
  • 8. Biocon Limited
  • 9. Boehringer Ingelheim GmbH
  • 10. Bristol-Myers Squibb Company
  • 11. Charles River Laboratories International, Inc.
  • 12. Eli Lilly and Company
  • 13. F. Hoffmann-La Roche AG
  • 14. GlaxoSmithKline plc
  • 15. Innovagen AB
  • 16. Johnson & Johnson Services Inc
  • 17. Lonza Group AG
  • 18. Merck KGaA
  • 19. Pfizer Inc.
  • 20. Sanofi S.A.
  • 21. Sartorius AG
  • 22. Sorrento Therapeutics, Inc.
  • 23. Sutro Biopharma, Inc.
  • 24. Thermo Fisher Scientific Inc.
  • 25. WuXi AppTec Co., Ltd

LIST OF FIGURES

  • FIGURE 1. BIOCONJUGATION MARKET MULTI-CURRENCY
  • FIGURE 2. BIOCONJUGATION MARKET MULTI-LANGUAGE
  • FIGURE 3. BIOCONJUGATION MARKET RESEARCH PROCESS
  • FIGURE 4. BIOCONJUGATION MARKET SIZE, 2023 VS 2030
  • FIGURE 5. GLOBAL BIOCONJUGATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL BIOCONJUGATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL BIOCONJUGATION MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL BIOCONJUGATION MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL BIOCONJUGATION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL BIOCONJUGATION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2023 VS 2030 (%)
  • FIGURE 19. GLOBAL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2030 (%)
  • FIGURE 21. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. AMERICAS BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. AMERICAS BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. UNITED STATES BIOCONJUGATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 25. UNITED STATES BIOCONJUGATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 27. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 28. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 29. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 30. BIOCONJUGATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 31. BIOCONJUGATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. BIOCONJUGATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL BIOCONJUGATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL BIOCONJUGATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. BIOCONJUGATION MARKET DYNAMICS
  • TABLE 7. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL BIOCONJUGATION MARKET SIZE, BY DOUBLE-STRANDED OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL BIOCONJUGATION MARKET SIZE, BY SINGLE-STRANDED OLIGONUCLEOTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL BIOCONJUGATION MARKET SIZE, BY PEPTIDE BIOCONJUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL BIOCONJUGATION MARKET SIZE, BY POLYMER BIOCONJUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL BIOCONJUGATION MARKET SIZE, BY PROTEIN BIOCONJUGATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL BIOCONJUGATION MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL BIOCONJUGATION MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL BIOCONJUGATION MARKET SIZE, BY ADC PROCESS DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL BIOCONJUGATION MARKET SIZE, BY ANALYTICAL DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL BIOCONJUGATION MARKET SIZE, BY DRUG SUBSTANCE MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL BIOCONJUGATION MARKET SIZE, BY EARLY DEVELOPMENT BIOCONJUGATE SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL BIOCONJUGATION MARKET SIZE, BY PAYLOAD & LINKER MANUFACTURING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL BIOCONJUGATION MARKET SIZE, BY TARGETING AGENT OR CARRIER PROTEIN SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL BIOCONJUGATION MARKET SIZE, BY AMIDE BOND FORMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIO-ORTHOGONAL REACTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL BIOCONJUGATION MARKET SIZE, BY CLICK CHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL BIOCONJUGATION MARKET SIZE, BY ENZYMATIC METHODS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL BIOCONJUGATION MARKET SIZE, BY THIOL-MALEIMIDE COUPLING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL BIOCONJUGATION MARKET SIZE, BY NATURAL BIOCONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL BIOCONJUGATION MARKET SIZE, BY SYNTHETIC BIOCONJUGATES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL BIOCONJUGATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL BIOCONJUGATION MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL BIOCONJUGATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL BIOCONJUGATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL BIOCONJUGATION MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL BIOCONJUGATION MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL BIOCONJUGATION MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL BIOCONJUGATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL BIOCONJUGATION MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL BIOCONJUGATION MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL BIOCONJUGATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL BIOCONJUGATION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL BIOCONJUGATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 66. ARGENTINA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 75. BRAZIL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. MEXICO BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. MEXICO BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 102. MEXICO BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED STATES BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED STATES BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED STATES BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 112. UNITED STATES BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 113. UNITED STATES BIOCONJUGATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 127. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 128. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 129. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 130. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 133. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 134. AUSTRALIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 135. CHINA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. CHINA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 137. CHINA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 138. CHINA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 139. CHINA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 140. CHINA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. CHINA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. CHINA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 143. CHINA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 144. CHINA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 145. INDIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. INDIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 147. INDIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 148. INDIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 149. INDIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 150. INDIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. INDIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. INDIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 153. INDIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 154. INDIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 155. INDONESIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. INDONESIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 157. INDONESIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 158. INDONESIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 159. INDONESIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 160. INDONESIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. INDONESIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 162. INDONESIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. INDONESIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 164. INDONESIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 165. JAPAN BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. JAPAN BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 167. JAPAN BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 168. JAPAN BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 169. JAPAN BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 170. JAPAN BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. JAPAN BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 172. JAPAN BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 173. JAPAN BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 174. JAPAN BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 175. MALAYSIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. MALAYSIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 177. MALAYSIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 178. MALAYSIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 179. MALAYSIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 180. MALAYSIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. MALAYSIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. MALAYSIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 183. MALAYSIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 184. MALAYSIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 185. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 187. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 188. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 189. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 190. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 192. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 193. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 194. PHILIPPINES BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 195. SINGAPORE BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. SINGAPORE BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 197. SINGAPORE BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 198. SINGAPORE BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 199. SINGAPORE BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 200. SINGAPORE BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 201. SINGAPORE BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 202. SINGAPORE BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 203. SINGAPORE BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 204. SINGAPORE BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 213. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 214. SOUTH KOREA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 215. TAIWAN BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. TAIWAN BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 217. TAIWAN BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 218. TAIWAN BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 219. TAIWAN BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 220. TAIWAN BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. TAIWAN BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. TAIWAN BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 223. TAIWAN BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 224. TAIWAN BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 225. THAILAND BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. THAILAND BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 227. THAILAND BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 228. THAILAND BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 229. THAILAND BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 230. THAILAND BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 231. THAILAND BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 232. THAILAND BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 233. THAILAND BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 234. THAILAND BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 235. VIETNAM BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. VIETNAM BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 237. VIETNAM BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 238. VIETNAM BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 239. VIETNAM BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 240. VIETNAM BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. VIETNAM BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 242. VIETNAM BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. VIETNAM BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 244. VIETNAM BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA BIOCONJUGATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 256. DENMARK BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. DENMARK BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 258. DENMARK BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 259. DENMARK BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 260. DENMARK BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 261. DENMARK BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. DENMARK BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 263. DENMARK BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 264. DENMARK BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 265. DENMARK BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 266. EGYPT BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 267. EGYPT BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 268. EGYPT BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 269. EGYPT BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 270. EGYPT BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 271. EGYPT BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. EGYPT BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 273. EGYPT BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 274. EGYPT BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 275. EGYPT BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 276. FINLAND BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. FINLAND BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 278. FINLAND BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 279. FINLAND BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 280. FINLAND BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 281. FINLAND BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 282. FINLAND BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 283. FINLAND BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. FINLAND BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 285. FINLAND BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 286. FRANCE BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. FRANCE BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 288. FRANCE BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 289. FRANCE BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 290. FRANCE BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 291. FRANCE BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 292. FRANCE BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 293. FRANCE BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 294. FRANCE BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 295. FRANCE BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 296. GERMANY BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 297. GERMANY BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 298. GERMANY BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 299. GERMANY BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 300. GERMANY BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 301. GERMANY BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. GERMANY BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 303. GERMANY BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 304. GERMANY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 305. GERMANY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 306. ISRAEL BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. ISRAEL BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 308. ISRAEL BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 309. ISRAEL BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 310. ISRAEL BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 311. ISRAEL BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 312. ISRAEL BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 313. ISRAEL BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 314. ISRAEL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 315. ISRAEL BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 316. ITALY BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. ITALY BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 318. ITALY BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 319. ITALY BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 320. ITALY BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 321. ITALY BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. ITALY BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 323. ITALY BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 324. ITALY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 325. ITALY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 326. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 327. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 328. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 329. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 330. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 331. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 333. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 334. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 335. NETHERLANDS BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 336. NIGERIA BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 337. NIGERIA BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 338. NIGERIA BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 339. NIGERIA BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 340. NIGERIA BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 341. NIGERIA BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 342. NIGERIA BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 343. NIGERIA BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 344. NIGERIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 345. NIGERIA BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 346. NORWAY BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 347. NORWAY BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 348. NORWAY BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 349. NORWAY BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 350. NORWAY BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 351. NORWAY BIOCONJUGATION MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 352. NORWAY BIOCONJUGATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 353. NORWAY BIOCONJUGATION MARKET SIZE, BY APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 354. NORWAY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC, 2018-2030 (USD MILLION)
  • TABLE 355. NORWAY BIOCONJUGATION MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2030 (USD MILLION)
  • TABLE 356. POLAND BIOCONJUGATION MARKET SIZE, BY BIOCONJUGATION TYPE, 2018-2030 (USD MILLION)
  • TABLE 357. POLAND BIOCONJUGATION MARKET SIZE, BY OLIGONUCLEOTIDE BIOCONJUGATION, 2018-2030 (USD MILLION)
  • TABLE 358. POLAND BIOCONJUGATION MARKET SIZE, BY OFFERING, 2018-2030 (USD MILLION)
  • TABLE 359. POLAND BIOCONJUGATION MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
  • TABLE 360. POLAND BIOCONJUGATION MARKET SIZE, BY TECHNIQUE, 2018-2030 (USD MILLION)
  • TABLE 361. POLAND BIOCONJUGATION MARKET SIZE, BY TYPE, 20